

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074969 A2

(51) International Patent Classification⁷: **C12N 15/87**

(21) International Application Number: **PCT/IB02/02137**

(22) International Filing Date: 28 January 2002 (28.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/264,355 26 January 2001 (26.01.2001) US
60/281,391 4 April 2001 (04.04.2001) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/281,391 (CIP)
Filed on	4 April 2001 (04.04.2001)
US	60/264,355 (CIP)
Filed on	26 January 2001 (26.01.2001)

(71) Applicant (for all designated States except US): **UNIVERSITY OF LAUSANNE** [CH/CH]; Rue de Bugnon 21, CH-1005 Lausanne (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MERMOD, Nicolas** [CH/CH]; c/o Unitectra, Schoenberggasse 2, CH-8001 Zurich (CH). **ZAHN-ZABAL, Monique** [CH/CH]; c/o Pactt, Rue de Bugnon 21, CH-1005 Lausanne (CH). **IMHOF, Markus** [CH/CH]; c/o Pactt, Rue de Bugnon

21, CH-1005 Lausanne (CH). **CHATELLARD, Philippe** [CH/CH]; c/o Pactt, Rue de Bugnon 21, CH-1005 Lausanne (CH). **GIROD, Pierre-Alain** [CH/CH]; c/o Pactt, Rue de Bugnon 21, CH-1005 Lausanne (CH).

(74) Agent: **BUGNION S.A.**; P.O. Box 375, CH-1211 Geneva 12 (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **MATRIX ATTACHMENT REGIONS AND METHODS FOR USE THEREOF**

(57) Abstract: The present invention relates to compositions and method for transfecting eukaryotic cells with nucleic acid vectors. In particular, the invention relates to uses of MAR elements to increase stable and transient transfection efficiency.

BEST AVAILABLE COPY

MATRIX ATTACHMENT REGIONS AND METHODS FOR USE THEREOF

Field of the Invention

The present invention relates generally to matrix attachment regions (MARs) and to
5 methods for use of MARs. In particular, the invention relates to the uses of such methods for
the development of stable eukaryotic cell lines.

Background of the Invention

Eukaryotic cell lines can be genetically modified to express one or more desired
10 proteins. Current selection and screening procedures to identify a clonal cell line with the
requisite expression characteristics for regulated expression or production are tedious and
time-consuming. For example, in Chinese hamster ovary (CHO) cells, the classical approach
to achieve maximal expression involves the use of mutant cell lines and a gradual increase in
the selection pressure over several months for a co-transfected selection marker such as
15 dihydrofolate reductase. (Kaufman and Sharp, 1982; Schimke et al., 1982) While new
approaches to the problem include the identification of rare sites on a chromosome with high
transcriptional activity, combined with targeted integration and the improvement of selection
and of screening procedures (Fussenegger et al., 1999), these are nevertheless all labor-
intensive processes.

20

Summary of the Invention

In one aspect, the present invention involves a method for transforming eukaryotic
cells using transfection of two or more unlinked nucleic acid vectors, the first vector having a
promoter and a heterologous gene coding for a desired protein, and the second vector having
25 at least one chromatin element. In preferred embodiments, the chromatin element is a MAR
element (*e.g.*, a chicken lysozyme MAR element). In alternative embodiments of the present
invention, the nucleic acid vectors are incorporated into the eukaryotic cell chromatin or
remain episomal.

In another aspect, the present invention involves a method for transforming eukaryotic
30 cells using transfection of two or more unlinked nucleic acid vectors, the first vector having a
promoter and a heterologous gene coding for a desired protein, and the second vector having
at least one chromatin element, and contacting the transfected cells with butyrate.

In yet another aspect, the present invention provides a method for transforming eukaryotic cells using transfection of two or more unlinked nucleic acid vectors, the first vector having a promoter, a heterologous gene coding for a desired protein and a first chromatin element; and the second vector having a second chromatin element. In alternative
5 embodiments, the first chromatin element may be located 5' (upstream) or 3' (downstream) of the promoter and the heterologous gene. In other embodiments, the second vector contains two or more chromatin elements (*e.g.*, a third, fourth, fifth or six chromatin element). In preferred embodiments of the present invention, at least one of the first, second, third, fourth, fifth and sixth chromatin elements may be MAR elements (*e.g.*, a chicken lysozyme MAR
10 element). In another preferred embodiment, the eukaryotic cell is co-transfected with a third vector. This third vector may include at least one genes (*e.g.*, structural, regulatory or selection genes) and/or at least one chromatin element (*e.g.*, a MAR element). In certain preferred embodiments of the present invention, the molar ratios of the first, second, and possibly third vectors are modulated.

15 In a further aspect, the present invention provides a method of selecting a eukaryotic cell expressing a gene encoding a recombinant proteins by transfecting a first eukaryotic cell with a first vector having a first promoter and a first gene, and a second vector having a MAR element and transfecting a second eukaryotic cell with the first vector having the first promoter and the first gene, measuring and comparing the expression of the gene in the first
20 and second eukaryotic cell, and selecting the first eukaryotic cell if the expression of the first gene is greater in the first eukaryotic cell than in the second eukaryotic cell.

In another aspect, the present invention provides compositions of one or more nucleic acid vectors. In one embodiment, the invention provides a composition of two nucleic acid vectors, the first vector having a promoter and a heterologous gene coding for a desired
25 protein, and the second vector having a MAR element. In other embodiments, the composition further comprises butyrate.

In another aspect, the present invention provides one or more eukaryotic cells containing two or more nucleic acid vectors, the first vector having a promoter and a heterologous gene coding for a desired protein, and the second vector having a MAR
30 element. In an embodiment, the invention provides or more eukaryotic cells containing two or more nucleic acid vectors, the first vector having a promoter, a heterologous gene coding for a desired protein and a MAR element, and the second vector having at least one MAR element. In some embodiments, the one or more eukaryotic cells are butyrate-treated cells.

In a further aspect, the present invention provides kits, containing in one or more containers, two or more nucleic acid vectors, the first vector having a promoter and a heterologous gene coding for a desired protein, and the second vector having a MAR element, and directions for use thereof. In an embodiment, the invention provides kits,
5 containing in one or more containers, one or more eukaryotic cells containing two or more nucleic acid vectors, the first vector having a promoter, a heterologous gene coding for a desired protein and a MAR element, and the second vector having at least one MAR element. In an embodiment, the kit additionally comprises butyrate.

Unless otherwise defined, all technical and scientific terms used herein have the same
10 meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the
15 present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and from the claims.

20

Brief Description of the Drawings

Fig.1 demonstrates the effect of chromatin elements on stable transgene expression. Chromatin elements were cloned on one or both sides of the luciferase expression unit (black line and arrow) of the pGL3-Control plasmid. The resulting constructs, shown schematically
25 in the left hand panel, were digested with PvuI and co-transfected with pSV2neo. The luciferase activity of pools of CHO clones, normalized with respect to protein content and expressed relative to pGL3-Control, is shown in the right hand panel. Error bars correspond to the standard error, based on at least three independent transfections. Chromatin elements examined include those chromatin elements potentially capable of overcoming position
30 effects, including boundary elements (BEs; black boxes), matrix attachment regions (MARs; white boxes), and locus control regions (LCRs; hatched boxes). The arrow depicting lys MAR orientation points from BamHI to XbaI, while the arrow for the LAP LCR points in the direction of the LAP gene and its direction of transcription.

Fig. 2 is a diagram that indicates stable reporter expression using the chicken lysozyme MAR. Constructs with one or two MARs cloned in pGL3-Control (pMZ50 and pMZ52 respectively), as well as the pGL3-Control and pUC-B-1-X1 plasmids in the indicated molar ratios were co-transfected with pSV2neo in CHO cells. The figure shows the luciferase activity of pools of clones, normalized with respect to protein content, and expressed relative to pGL3-Control. Error bars correspond to the standard error, based on at least three independent transfections.

Fig. 3 demonstrates gene expression in stable CHO clones. Fig. 3A shows luciferase expression for clones obtained with either pGL3-Control, pMZ50, or pMZ52, corresponding to plasmids bearing no, one, or two chicken lysozyme MARs. Luciferase activity, normalized with respect to protein content, is shown for 15 clones for each construct, ranked from lowest to highest expression level. Fig. 3B shows anti-Rhesus D IgG1 antibody expression for clones obtained by co-transfecting the light and heavy chain expression vectors, pMZ57 and pMZ36 respectively, with the indicated molar ratios of either control pUC18 or MAR-bearing pUC-B-1-X1 plasmid. Supernatant antibody concentration is shown for clones ranked from lowest to highest expression level. Fig. 3C demonstrates the molecular analysis of anti-Rhesus D antibody-expressing clones. The top panel shows a schematic diagram of the pUC-B-1-X1 vector, with the hatched box corresponding to the MAR sequence. Fragment sizes obtained upon digestion are indicated above the map. The bottom panel shows the results of a Southern blot analysis of four stable cell clones with the MAR from panel B (labeled #1 – #4). Genomic DNA was digested with EcoRI and probed with the entire MAR sequence. The molecular mass of fragments is given in kilobase pairs on the left.

Fig. 4 shows the regulated gene expression in stable C2C12 clones. Fig. 4A depicts the screening of randomly picked stable C2C12 clones with the repressor construct. The luciferase activity, normalized with respect to β -galactosidase activity, is shown for 24 clones. White columns correspond to expression in the absence of doxycycline (no dox); black columns correspond to expression induced by the addition of doxycycline (dox), with the fold induction indicated above the black column. Fig. 4B shows the expression in clones selected by FACS with the stably integrated regulated expression system. The β -galactosidase activity, normalized with respect to protein content, is shown for 10 clones.

White columns correspond to expression in the absence of doxycycline (no dox); black columns correspond to expression induced by the addition of doxycycline (dox), with the fold induction indicated above the black column.

5 Fig. 5 demonstrates the effect of MARs on IgG productivity in CHO cells. Fold induction of SV40-promoter (*panel A*) and CMV-promoter (*panel B*) driven expression of recombinant IgG with different combinations of MARs. Results are expressed as means of specific productivity of pools of stably transfected cells from two experiments done in triplicates. Specific productivity of single cell clones with 1 MARs in cis + 4 MAR in trans
10 ranged up to 38 pg/cell/day and 40 pg/cell/day with the SV40 and CMV promoter, respectively. Transfections are as generally described in the art, (See *e.g.*, Zahn-Zabal et al., 2001 J. Biotechnol. 87:29, and *infra*) using plasmids pMZ36, pMZ37, pMZ57 and pMZ59. Plasmid used for the expression of IgG containing one MAR element in cis (1 MAR in cis) were constructed as described in Example 1.

15

 Fig. 6 demonstrates the effect of MAR elements and sodium butyrate on IgG secretion in transiently transfected CHO cells by indicating the time-course accumulation of IgG (μ g) per 1.3 ml of culture medium supernatant in a single well of a 24-well plate (the average of triplicate wells is shown). In the left panel, cells were transfected with 1.69 μ g of control
20 (first two rows of columns) or with equimolar amount (2.28 μ g) of MAR- containing plasmids (rows 3 and 4) per three wells. The ratio between the heavy and light chain-encoding plasmids was 2:1. The total amount of plasmid DNA was adjusted to 2.5 μ g with pGL3 (Promega, Inc). Rows 2 and 4 result from cell treated by the addition of 10 mM sodium butyrate in the culture medium. In the right panel cells were transfected with 2.47 μ g
25 of control (first two rows of columns) or with equimolar amount (3.27 μ g) of MAR- containing plasmids (rows 3 and 4) per three wells, respectively. The ratio between the heavy and light chain-encoding plasmids was 2:1. Rows 2 and 4 result from cell treated by the addition of 10 mM sodium butyrate in the culture medium.

30 Figure 7. demonstrates the effect of MAR fragments on a reporter luciferase gene in stably transfected CHO cells. Figure 7A shows a map for the MAR fragment-linked luciferase gene constructs. The pML construct shows the natural MAR sequence, arbitrarily segmented in parts A, B, C, D, E, F, G and K, the SV40 early promoter, as indicated by the SV40-labelled box, and the luciferase reporter transgene. Construct pLM has the luciferase

transgene placed between the SV40 promoter and natural MAR sequence. Other constructs shown in Example 7 pML contain multimerized portions of the MAR element as indicated. The DNA sequence of the MAR segments is provided in Example 7. Figure 7B shows the results of luciferase measurements performed with extracts of cells containing a reporter
5 construct lacking MAR sequence (pGL3) or derivatives containing in cis one copy of the natural MAR sequences (pML, pLM), or containing multimerized MAR elements as indicated in part (A). Analyses were performed with G-418 selected populations (polyclonal pools of stably transfected CHO cells), as in the art. The results represent data from two independent sets of experiments.

10

Detailed Description of the Invention

To date, the development of stable cell lines has been hampered by the negative effects of surrounding chromatin on the expression of randomly integrated vector sequences. Chromatin elements, such as boundary elements, matrix attachment regions, and locus
15 control regions, are known to exert an effect on gene expression only when integrated in the genome. While the use of chromatin elements in the next generation of gene therapy vectors is currently being considered to improve expression of therapeutic transgenes (Neff et al., 1997), few studies have systematically addressed the potential of such elements to modify or
20 improve the expression of gene constructs. In order to exploit the favorable properties of chromatin elements in the development of stable cell lines, their usefulness must be established. The elements used to this end should improve the frequency of obtaining high-level expression clones, irrespective of the chromosomal integration site and the number of copies integrated. This effect should not be specific to a particular cell type, but rather should
25 be observed in all cell lines commonly used in biotechnology and gene or cell therapy. Furthermore, the element should act independently of the promoter, enabling it to be used with diverse constructs.

The compositions and methods according to the present invention possess new capacities and abilities in the transfection of eukaryotic cells. The present invention enables
30 the transfection of nucleic acids, such as genes encoding recombinant proteins, into eukaryotic cells, particularly mammalian cells.

The compositions and methods according to the present invention are particularly suited for generating cell lines that express one or more genes encoding for recombinant proteins.

Variability in expression levels of a heterologous gene transfected into a eukaryotic cell is thought to reflect the influence of the chromatin structure and/or the presence of regulatory elements at the site of integration of the heterologous gene in the host genome, a phenomenon referred to as the "position effect". A simple and rapid approach to overcome position effects is to make use of chromatin elements that prevent the neighboring chromatin from affecting transgene expression. This approach improves the probability of isolating a clone exhibiting the desired regulated expression. This approach is useful, *e.g.*, for *ex vivo* gene therapy, or for high-level expression for production of a recombinant protein, thereby reducing the time spent screening clones. Furthermore, position-independent transgene expression has significant potential in the construction of regulated gene expression systems, because the expression of a therapeutic gene (along with its controlling components) would be independent of the chromatin structure at the integration site. Chromatin elements that are potentially capable of overcoming position effects, and hence are of interest for the development of stable cell lines, include boundary elements (BEs), matrix attachment regions (MARs), locus control regions (LCRs), and universal chromatin opening elements (UCOE).

Boundary elements ("BEs"), or insulator elements, define boundaries in chromatin in many cases (Bell and Felsenfeld, 1999; Udvardy, 1999) and may play a role in defining a transcriptional domain *in vivo*. BEs lack intrinsic promoter/enhancer activity, but rather are thought to protect genes from the transcriptional influence of regulatory elements in the surrounding chromatin. The enhancer-block assay is commonly used to identify insulator elements. In this assay, the chromatin element is placed between an enhancer and a promoter, and enhancer-activated transcription is measured. Boundary elements have been shown to be able to protect stably transfected reporter genes against position effects in *Drosophila*, yeast and in mammalian cells (Bi and Broach, 1999; Cuvier et al., 1998; Walters et al., 1999). They have also been shown to increase the proportion of transgenic mice with inducible transgene expression (Wang et al., 1997).

Matrix Attachment Regions ("MARs"; also known as Scaffold Attachment Regions or Scaffold/Matrix Attachment Regions ("S/MARs")) are DNA sequences that bind isolated nuclear scaffolds or nuclear matrices *in vitro* with high affinity (Hart and Laemmli, 1998). As such, they may define boundaries of independent chromatin domains, such that only the

encompassing *cis*-regulatory elements control the expression of the genes within the domain. However, their ability to fully shield a chromosomal locus from nearby chromatin elements, and thus confer position-independent gene expression, has not been seen in stably transfected cells (Poljak et al., 1994). On the other hand, MAR sequences have been shown to interact
5 with enhancers to increase local chromatin accessibility (Jenuwein et al., 1997). Specifically, MAR elements can enhance expression of heterologous genes in cell culture lines (Kalos and Fournier, 1995; Klehr et al., 1991; Phi-Van et al., 1990; Poljak et al., 1994), transgenic mice (Castilla et al., 1998) and plants (Allen et al., 1996). The utility of MAR sequences for developing improved vectors for gene therapy is also recognized (Agarwal et al., 1998).

10 Locus control regions ("LCRs") are *cis*-regulatory elements required for the initial chromatin activation of a locus and subsequent gene transcription in their native locations (reviewed in Grosveld, 1999). The activating function of LCRs also allows the expression of a coupled transgene in the appropriate tissue in transgenic mice, irrespective of the site of integration in the host genome. While LCRs generally confer tissue-specific levels of
15 expression on linked genes, efficient expression in nearly all tissues in transgenic mice has been reported for a truncated human T-cell receptor LCR (Ortiz et al., 1997) and a rat LAP LCR (Talbot et al., 1994). The most extensively characterized LCR is that of the globin locus. Its use in vectors for the gene therapy of sickle cell disease and β -thalassemias is currently being evaluated (Pawliuk et al., 1998).

20 Ubiquitous chromatin opening elements ("UCOE", also known as "ubiquitously-acting chromatin opening elements") have recently been reported (See WO00/05393).

The chicken lysozyme 5' MAR element is able to significantly improve stable transgene expression in CHO cells, a cell line commonly used in recombinant protein production. The chicken lysozyme 5' MAR element is also able to significantly improve
25 transient transfections, particularly when the transfected cells are contacted with butyrate. This chicken MAR element has previously been shown to enhance transcription from a heterologous promoter in heterologous cells (Phi-Van et al., 1990), and to confer position-independent hormonal and developmental regulation of the expression of the whey acidic protein gene in transgenic mice (McKnight et al., 1992).

30 Importantly, co-transfection of a plasmid bearing the chicken lysozyme 5' MAR element with one or more expression vectors results in increased stable transgene expression. This simple approach obviates the necessity of cloning MAR elements in expression constructs. Furthermore, the size of the MAR element is no longer a limitation. Co-transfection with the MAR element is shown to increase the average level of expression of

stable clones, as well as to increase the probability of obtaining clones expressing at higher levels than those obtained upon transfection of the expression plasmids alone.

Without wishing to be bound by theory, it is possible that the distance and sequence between the MAR elements and the expression unit is an important consideration. The effect of MARs has been detected for a proximal gene, and not for a more distally located one (Bode et al., 1995). The effect of co-transfection of the MAR has not found to be saturated (See Fig. 2), a potential limitation of this technique is the quantity of DNA that can be transfected per cell. One skilled in the art would be able to determine the maximum quantity of DNA to transfect for a given cell type with minimal experimentation.

As used herein, the following definitions are supplied in order to facilitate the understanding of this case. To the extent that the definitions vary from meanings circulating within the art, the definitions below are to control.

"Chromatin" is the nucleic acid material having the chromosomes of a eukaryotic cell, and refers to DNA, RNA and associated proteins.

A "chromatin element" means a nucleic acid sequence on a chromosome.

"Cis" refers to the placement of two or more elements (such as chromatin elements) on the same nucleic acid molecule (such as the same vector or chromosome).

"Trans" refers to the placement of two or more elements (such as chromatin elements) on two or more different nucleic acid molecules (such as on two vectors or two chromosomes).

"Cis activation" refers to activation of a gene by an activator (such as an enhancer) located on the same nucleic acid molecule (such as the same vector or chromosome).

"Downstream" refers to the direction going towards the 3' end of a nucleotide sequence.

An "enhancer" is a nucleotide sequence that acts to potentiate the transcription of genes independent of the identity of the gene, the position of the sequence in relation to the gene, or the orientation of the sequence. The vectors of the present invention optionally include enhancers.

A "gene" is a deoxyribonucleotide (DNA) sequence coding for a given mature protein. As used herein, the term "gene" shall not include untranslated flanking regions such as RNA transcription initiation signals, polyadenylation addition sites, promoters or enhancers.

A "selection gene" is a gene that confers a phenotype on cells which express the gene as a detectable protein. Examples of selection genes include, but are not limited to, antibiotic

resistance genes and genes encoding enzymes that produce or modify intermediate compounds of cellular metabolism or compounds exogenously added to the cell (*e.g.*, drugs).

A "selection agent" is a condition, agent or substance that enables the detection of the expression of a selection gene.

5 "Phenotype" refers to the observable properties of a cell as expressed by the cellular genotype.

A "product gene" is a gene that encodes a protein product having desirable characteristics such as diagnostic or therapeutic utility. A product gene includes, *e.g.*, structural genes and regulatory genes.

10 A "structural gene" refers to a gene that encodes a structural protein. Examples of structural genes include but are not limited to, cytoskeletal proteins, extracellular matrix proteins, enzymes, nuclear pore proteins and nuclear scaffold proteins, ion channels and transporters, contractile proteins, and chaperones. Preferred structural genes encode for antibodies or antibody fragments.

15 A "regulatory gene" refers to a gene that encodes a regulatory protein. Examples of regulatory proteins include, but are not limited to, transcription factors, hormones, growth factors, cytokines, signal transduction molecules, oncogenes, proto-oncogenes, transmembrane receptors, and protein kinases.

20 "Genotype" refers to the genetic information contained within a cell as opposed to its expression, which is observed as the cellular phenotype.

"Ligation" is the process for forming a phosphodiester bond between the 5' and 3' ends of two DNA strands. This may be accomplished by several well known enzymatic techniques, including, but not limited to, blunt end ligation by T4 DNA ligase.

25 "Orientation" refers to the order of nucleotides in a given DNA sequence. For example, an inverted orientation of a DNA sequence is one in which the 5' to 3' order of the sequence in relation to another sequence is reversed when compared to a point of reference in the DNA from which the sequence was obtained. Such reference points can include the direction of transcription of other specified DNA sequences in the source DNA and/or the origin of replication of replicable vectors containing the sequence.

30 "Transcription" means the synthesis of RNA from a DNA template.

"Translation" refers to the synthesis of a polypeptide from messenger RNA.

The term "vector" as used herein refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.

"Eukaryotic cell" refers to any mammalian or non-mammalian cell from a eukaryotic organism. By way of non-limiting example, any eukaryotic cell which is capable of being maintained under cell culture conditions and subsequently transfected would be included in this invention. Especially preferable cell types include, *e.g.*, stem cells, embryonic stem cells,
5 Chinese hamster ovary cells (CHO), COS, BHK21, NIH3T3, HeLa, C2C12, cancer cells, and primary differentiated or undifferentiated cells. Other suitable host cells are known to those skilled in the art.

"Transformation" as used herein refers to modifying a eukaryotic cell by the addition of a nucleic acid. For example, transforming a cell could include transfecting the cell with a
10 nucleic acid, such as a DNA vector.

"Transfection" is the introduction of a nucleic acid into a recipient eukaryotic cell, such as by electroporation or by chemical means. Transfection may be detected in some cases by an alteration in cell phenotype. In some cases, transfected cells are called transfectants and pre-transfection cells are referred to as parental cells.

15 "Promoter" as used herein refers to a nucleic acid sequence that regulates expression of a gene.

"Co-transfection" means the process of transfecting a eukaryotic cell with more than one exogenous gene foreign to the cell, one of which may confer a selectable phenotype on the cell.

20 Eukaryotic transfection of nucleic acid vectors is, in general, a well-known process, and may be accomplished by a variety of standard methods. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous
25 replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are
30 operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. As used herein, "plasmid" and "vector" are used interchangeably, as the plasmid is the most commonly used vector form. However, the invention is intended to include such other forms of expression vectors, including, but not limited to, viral vectors (*e.g.*, replication

defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention contain a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. Specifically, this means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, the term "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transfected, the level of expression of protein desired, etc.

The recombinant expression vector(s) used herein can be designed for expression of desired proteins in eukaryotic cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).

The expression vector(s) used herein may be a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

Alternatively, the expression vector(s) used herein may be a baculovirus expression vector. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, *et al.*, 1983. *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. *Virology* 170: 31-39).

A nucleic acid of the invention may also be expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO J.* 6: 187-195).

When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, *e.g.*, Chapters 16 and 17 of Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

A recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed. Examples of such promoters include, *e.g.*, the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the α -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

Regulatable gene expression promoters are well known in the art, and include, by way of non-limiting example, any promoter that modulates expression of a gene encoding a desired protein by binding an exogenous molecule, such as the CRE/LOX system, the TET system, the NFkappaB/UV light system, the Leu3p/isopropylmalate system, and the GLVPc/GAL4 system (See *e.g.*, Sauer, 1998, *Methods* 14(4): 381-92; Lewandoski, 2001, *Nat. Rev. Genet* 2(10):743-55; Legrand-Poels *et al.*, 1998, *J. Photochem. Photobiol. B.* 45:1-8; Guo *et al.*, 1996, *FEBS Lett.* 390(2):191-5; Wang *et al.*, *PNAS USA*, 1999, 96(15):8483-8).

Moreover, the terms "host cell" and "recombinant host cell" are used interchangeably herein to indicate a eukaryotic cell into which one or more vectors of the invention have been introduced. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such

progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

As noted, the term "transfection" refers to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these successful integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a structural or regulatory protein, or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

The present invention involves compositions and methods that can modulate the efficiency of eukaryotic cell transfection using chromatin elements (*e.g.*, MAR elements, BEs and LCRs). In accordance with the invention, MAR elements may be used in eukaryotic cell transfection methods. For example, a MAR element suitable for use in the present invention includes chicken lysozyme MAR element, which is shown in SEQ ID NO: 1 (See Table 1A) or a fragment thereof. Also useful are the nucleotide sequences recited in GenBank Accession numbers X52989 (SEQ ID NO: 2), X84223 (SEQ ID NO: 3), X98408 (SEQ ID NO: 4), and AJ277960 (SEQ ID NO: 5) (See Tables 1B-1E) or fragments thereof. Additional MAR elements to be used in accordance with the invention may be identified, isolated, and cloned using a variety of techniques well known to those of ordinary skill in the art.

TABLE 1A. MAR Element (SEQ ID NO: 1)

tctagaaaacaatatatttccaaatgaaaaaaaaaatctgataaaaagttg actttaaaaagtatcaataaatgtatgcatttctcactagccttaaac ctgcatgaagtgtttgatgagcagatgaagacaacatcatttctagtttc

agaaataataacagcatcaaaaccgcagctgtaactccactgagctcacg
 ttaagttttgatgtgtgaatatctgacagaactgacataatgagcactgc
 aaggatatcagacaagtcacaaatgaagacagacaaaagtattttttaata
 taaaaatgggtctttatttcttcaatacaaggtaaaactactattgcagttt
 aagaccaacacaaaagtggacagcaaatgtttaacagctctcctaaagg
 ctgaaaaaaagggaacccatgaaagctaaaaagtattgcagttattcaagta
 taacatctaaaaatgatgaaacgatccctaaaggtagagattaactaagt
 acttctgctgaaaaatgtattaaaaatccgcagttgctaggataccatctta
 ccttgttgagaaaatcacaggtctccggcaacgcaacattcagcagactcct
 tggcctgctgggaatcaggaactgcttactatatacacatataaatcctt
 tggagtggggcattctgagagacatccatttctgacattttgcagtgca
 actctgcatttccaaactcagacaagctcccatgctgtatttcaaaagccatt
 tcttgaatagttttaccagacatccttgtgcaaatgtgggaatgaggaaat
 gcaatgggtacaggaagacaataacagccttatgttttagaaagtcagcagcg
 ctggtaactcttcataaaaaatgtaactgttttccaaatagggaatgtatttc
 acttgtaaaaacacctgggtccttttatattactttttttttttttaagg
 acacctgcactaatttgcaatcacttgtatttataaaagcacacgcactc
 ctcatcttcttactattgaaagatcagcagaatgtctcttccataatgtaa
 taatcatatgcacagtttaaaatattttctattacaaaatacagtacaca
 agaggggtgaggccaaagtctattacttgaatatattccaaagtgtcagca
 ctgggggtgtaaaattacattacatgggtatgaataggcggaattctttta
 caactggatctctcgatttctattgggatcaaaggtaagtactgtttacta
 tcttcaagagacttcaatcaagtgggtgtatttccaaagaagcttaaaag
 attgaagcacagacacaggccacaccagagcctacacctgctgcaataag
 tgggtgctatagaaaggattcaggaactaacaagtgcataatttacaata
 gagatgctttatcatatcttgcacacatgggaaaaaagacatcccatga
 gaatatccaaactgaggaacttctctgtttcatagtaactcatctactact
 gctaagatgggttgaaaagtacccagcaggtgagatatttccgggaggtg
 gctgtgtggcagctgttcccaacacgacacaaaagcacccaccctatct
 gcaatgctcactgcagggcagtgccgttaaacagctgcaacaggcatcact
 tctgcataaatgtgtgactcgttagcatgctgcaactgtgtttaaacc
 tatgcactccgttaccaaaaataatttaagtcccaataaatccatgcagc
 ttgcttctatgcacacataattttagaaagtattcattcttctttaagaa
 tatgcacgtggatctacacttcttgggatctgaagcgatttatacctcag
 ttgcagaagcagtttagtgtctggatctgggaaggcagcagcaaacgtg
 ccggttttacatttgaacccatgtgacaacccgccttactgagcatcgct
 ctaggaaaatttaaggctgtatccttacaacacagaacacagcagact
 gcataataaaattctataataaaaaataggagtgaagtctgtttgacctgt
 acacacagagcatagagataaaaaaaaaggaaatcaggaattacgtatt
 tctataaatgccatatatttttactagaacacagatgacaagtatatac
 aacatgtaaatcgaagttatcaacatgttaactaggaaaacatttaca
 gcatttgggtatgcaactagatcatcaggtaaaaaatccattagaaaaa
 tctaagcctcgccagtttcaaaaggaaaaaacagagaacgctcactact
 tcaaaggaaaaaaaataaagcatcaagctggcctaaacttaataagggtat
 ctcatgtaacaacagctatccaagctttcaagccacactataaataaaaa
 cctcaagttccgatcaacgttttccataatgcaatcagaaccaaaggcat
 tggcacagaaagcaaaaagggaatgaaagaaaagggtgtacagtttcca
 aaagggttcttctttgaagaaatgtttctgacctgtcaaaacatacagtc
 cagtagaaattttactaagaaaaaagaacaccttacttaaaaaaaa
 caacaaaaaaaacaggcaaaaaaacctctcctgtcactgagctgccacca
 cccaaccaccactgctgtgggctttgtctcccaagacaaaggacacaca
 gccttatccaatattcaacattacttataaaaacgctgatcagaagaaat
 accaagtatttctcagagactgttatatcctttcatcggaacaagaga
 tgaaatacaacagagtgaatatcaaagaaggcgaggagccaccgtggc
 accatcacgggagtgagtgcccaactgcccgtttctgagcacgcata
 ggaagccgtcagtcacatgtaataaaccaaaacctgggtacagttatatta
 tggatcc

TABLE 1B. MAR Element (Accession NO: X52989; SEQ ID NO: 2)

gcgctgctga	ctttctaaac	ataaggctgt	attgtcttcc	tgtaccattg	catttctca
ttcccaattt	gcacaaggat	gtctgggtaa	actattcaag	aatgggcttt	gaaatacagc
atgggagctt	gtctgagttg	gaatgcagag	ttgcaactgca	aatgtcagg	aatggatgt
ctctcagaat	gccaactcc	aaaggattta	tatgtgtata	tagtaagcag	tttcttgatt
ccagcaggcc	aaagagtctg	ctgaatgttg	cgttgccgga	gacctgtatt	tctcaacaag
gtaagatggg	atcctagcaa	ctgcccgttt	taatacattt	tcagcagaag	tacttagtta

atctctacct	ttagggatcg	tttcatcatt	tttagatggt	atacttgaaa	tactgcataa
cttttagctt	tcatgggttc	ctttttttca	gccttttagga	gactgttaag	caatttgctg
tccaactttt	gtgttgggtc	taaactgcaa	tagtagttta	ccttgatttg	aagaaataaa
gaccattttt	atattaaaaa	atacttttgt	ctgtcttcat	tttgacttgt	ctgatatcct
tgcagtgtc	attatgtcag	ttctgtcaga	tattcacaca	tcaaaactta	acgtgagctc

TABLE 1C. MAR Element (Accession No: X84223; SEQ ID NO: 3)

aagcttcttt	ggaaatacac	cgacttgatt	gaagtctctt	gaagatagta	aacagtactt
acctttgatc	ccaatgaaat	cgagcatttc	agttgtaaaa	gaattccgcc	tattcatacc
atgtaatgta	attttacacc	cccagtgctg	acacttttga	atatattcaa	gtaatagact
ttggcctcac	cctcttgtgt	actgtatttt	gtaatagaaa	atatttttaa	ctgtgcatat
gattattaca	ttatgaaaga	gacattctgc	tgatcttcaa	atgtaagaaa	atgaggagt
cgtgtgcttt	tataaatata	agtgattgca	aattagtgc	ggtgtcctta	aaaaaaaaaa
aaagtaatat	aaaaaggacc	aggtgtttta	caagtgaat	acattcctat	ttggaaaaca
gttacatttt	tatgaagatt	accagcgct			

TABLE 1D. MAR Element (Accession No: X98408; SEQ ID NO: 4)

ggatccataa	tataactgta	ccagggtttt	gtttattaca	tgtgactgac	ggcttccctat
gcgtgctcag	aaaacggcag	ttgggcactg	cactgcccgg	tgatgggtgcc	acggtggctc
ctgccgcctt	ctttgatatt	cactctgttg	tatttcactc	cctgttgccg	atgaaaggat
ataacagtct	ctgaggaaat	acttggtatt	tcttctgata	agcgttttta	taagtaatgt
tgaatattgg	ataaggctgt	gtgtcctttg	tcttgggaga	caaagcccac	agcaggtgggt
ggttgggtgg	tggcagctca	gtgacaggag	agggtttttt	gcctgttttt	tttgtgtttt
ttttttttta	agtaagggtgt	tcttttttct	tagtaaaatt	tctactggac	tgtatgtttt
gacaggtcag	aaacatttct	tcaaaagaag	aaccttttgg	aaactgtaca	gcccttttct
ttcattccct	ttttgctttc	tgtgccaatg	cctttgggtc	tgattgcatt	atggaaaacg
ttgatcggaa	cttgagggtt	ttatttatag	tgtggcctga	aagcttggat	agctgttgtt
acatgagata	ccttattaag	tttaggccag	cttgatgctt	tatttttttt	cctttgaagt
agtgagcggt	ctctgggttt	tttcctttga	aactggcgag	gcttagattt	ttctaattgg
attttttacc	tgatgatcta	gttgcatacc	caaagtcttg	taaatgtttt	cctagttaac
atgttgataa	cttcggattt	acatgttgta	tatacttgtc	atctgtgttt	ctagtaaaaa
tatatggcat	ttatagaaat	acgtaattcc	tgatttcctt	ttttttttat	ctctatgctc
tgtgtgtaca	ggtcaaacag	acttcactcc	tattttttat	tatagaattt	tatatgcagt
ctgtcggttg	ttcttgtgtt	gtaaggatac	agccttaaat	ttcctagagc	gatgctcagt
aaggcgggtt	gtcacatggg	ttcaaagtga	aaacgggcac	gtttgctgct	gccttcccag
atccaggaca	ctaaactgct	tctgcaactg	aggtataaat	cgcttcagat	cccaggaagt
gtagatccac	gtgcatattc	ttaaagaaga	atgaatactt	tctaaaatat	gttggcatag
gaagcaagct	gcatggattt	atttgggact	ttaattattt	tggtaacgga	gtgcatagggt
tttaaacaca	gttgagcat	gctaacgagt	cacagcattt	atgcagaagt	gatgcctgtt
gcagctgttt	acggcactgc	cttgagtgta	gcattgcaga	taggggtggg	gtgctttgtg
tcgtgttggg	acacgctgcc	acacagccac	ctcccgaaca	tatctcacct	gctgggtact
tttcaaacca	tcttagcagt	agtagatgag	ttactatgaa	acagagaagt	tcctcagttg
gatattctca	tgggatgtct	tttttcccat	gttggggcaa	gtatgataaa	gcattcttat
ttgtaaatga	tgcacttgtt	agttcctgaa	tcctttctat	agcaccactt	attgcagcag
gtgtaggctc	tgggtgtggc	tgtgtctgtg	cttcaatctt	ttaagctt	

TABLE 1E. MAR Element (Accession No: AJ277960; SEQ ID NO: 5)

aggtcactgt	gacctagatc	cgcaggtcac	tgtgacctac	atctgatata	atcgctcgacg
gtatcgataa	gcttcgaccg	atccggcccc	gcccagcgtc	ttgtcattgg	cgaattcgaa
cacgcagatg	cagtcggggc	ggcggggtcc	gagggtccact	tcgcatatta	aggtgacgcg
tgtggcctcg	aacaccgagc	gaccctgcag	cgaccgcgtt	aacagcgctca	acagcgtgcc
gcagatctcg	agagatctcg	aggcatgcaa	gcttggcatt	ccggtactgt	tggtaaaatg
gaagacgcc	aaaacataaa	gaaaggcccg	gcgccattct	atcctctaga	ggatggaacc

gctggagagc	aactgcataa	ggctatgaag	agatacgccc	tggttcctgg	aacaattgct
tttacagatg	cacatatcga	ggtgaacatc	acgtacgcgg	aatacttcga	aatgtccggt
cggttggcag	aagctatgaa	acgatatggg	ctgaatacaa	atcacagaat	cgtcgtatgc
agtgaaaact	ctcttcaatt	ctttatgccg	gtggtgggcg	cgttatttat	cggagttgca
gttgcgcccc	cgaacgacat	ttataatgaa	cgtgaattgc	tcaacagtat	gaacatttcg
cagcctaccg	tagtgtttgt	ttccaaaaag	gggttgcaaa	aaattttgaa	cgtgcaaaaa
aaattaccaa	taatccagaa	aattattatc	atggattcta	aaacggatta	ccagggattt
cagtcgatgt	acacgttcgt	cacatctcat	ctacctcccc	gttttaatga	atacgatttt
gtaccagagt	cctttgatcg	tgacaaaaca	attgcaactg	taatgaattc	ctctggatct
actgggttac	ctaagggtgt	ggcccttcgc	catagaactg	cctgcgtcag	attctcgcat
gccagagatc	ctatttttgg	caatcaaate	attccggata	ctgcgatttt	aagtgttgtt
ccattccatc	acggttttgg	aatgtttact	acactcggat	atttgatatg	tggatttcga
gtcgtcttaa	tgtatagatt	tgaagaagag	ctgtttttac	gatcccttca	ggattacaaa
attcaaagtg	cgttgctagt	accaacccta	ttttcattct	tcgccaaaag	cactctgatt
gacaaaatcg	atttatctaa	tttacacgaa	attgcttctg	ggggcgcacc	cttttcgaaa
gaagtcgggg	aagcgggtgc	aaaacgcttc	catcttccag	ggatacgaca	aggatatggg
ctcactgaga	ctacatcagc	tattctgatt	acacccgagg	gggatgataa	accgggcgcg
gtcggtaaag	ttgttccatt	ttttgaagcg	aagggtgtgg	atctggatac	cgggaaaacg
ctgggcggtt	atcagagagg	cgaattatgt	gtcagaggac	ctatgattat	gtccggttat
gtaacaatc	cggaaagcag	caacgccttg	attgacaagg	atggatggct	acattctgga
gacatagctt	actgggacga	agacgaacac	ttcttcatag	ttgacgcgtt	gaagtcttta
attaaataca	aaggatatca	gggtggcccc	gctgaattgg	aatcgatatt	gttacaacac
cccaacatct	tcgacgcggg	cgtggcaggt	cttcccgacg	atgacgcggg	tgaacttccc
gccgccggtt	ttgttttggg	gcacggaaag	acgatgacgg	aaaaagagat	cgtggattac
gtggccagtc	aagtaacaac	cgcgaaaaag	ttgcgcggag	gagtttgtgt	tgtggacgaa
gtaccgaaag	gtcttaccgg	aaaactcgac	gcaagaaaaa	tcagagagat	cctcataaag
gccaaagaag	gcggaaagtc	caaattgtaa	aatgtaactg	tattcagcga	tgacgaaatt
cttagctatt	gtaatactgc	gatgagtggc	agggcggggc	gtaatttttt	taaggcagtt
attggtgccc	ttaaacgcct	ggtgctacgc	ctgaataagt	gataataagc	ggatgaatgg
cagaaattcg	ccggatcttt	gtgaaggaac	cttacttctg	tgggtgtgaca	taattggaca
aactacctac	agagatttaa	agctctaagg	taaatataaa	atttttaagt	gtataatgtg
ttaaactact	gattctaatt	gtttgtgtat	tttagattcc	aacctatgga	actgatgaat
gggagcagtg	gtggaatgcc	tttaattgag	aaaacctggt	ttgctcagaa	gaaatgccat
ctagtgatga	tgaggctact	gctgactctc	aacattctac	tcctccaaaa	aagaagagaa
aggtagaaga	ccccaggac	tttccttcag	aattgctaag	ttttttgagt	catgctgtgt
ttagtaatag	aactcttgct	tgtctttgct	tttacaccac	aaaggaaaaa	gctgcactgc
tatacaagaa	aattatggaa	aaatattctg	taacctttat	aagtaggcat	aacagttata
atcataacat	actgtttttt	cttactccac	acaggcatag	agtgtctgct	attaataact
atgctcaaaa	atttgtgtacc	tttagctttt	taatttgtaa	aggggttaat	aaggaaatatt
tgatgtatag	tgccttgact	agagatcata	atcagccata	ccacatttgt	agaggtttta
cttgcttttaa	aaaacctccc	acacctcccc	ctgaacctga	aacataaaaat	gaatgcaatt
gttggtgtta	acttgtttat	tgcagcttat	aatggttaca	aataaagcaa	tagcatcaca
aatttcacaa	ataaagcatt	tttttcaactg	cattctagtt	gtggtttgtc	caaactcatc
aatgtatctt	atcatgtctg	gatccgtcga	gggggatcca	ctagttctag	agcggccgcc
accgggatcc	ataatataac	tgtaccagggt	tttggtttat	tacatgtgac	tgacggcttc
ctatgcgtgc	tcagaaaacg	gcagttgggg	actgcactgc	ccggtgatgg	tgccacgggtg
gctcctgccc	ccttcittga	tattcactct	gttgatattc	atctcttggt	gccgatgaaa
ggatataaca	gtctctgagg	aaatacttgg	tatttcttct	gatcagcggt	tttataagta
atggtgaata	ttggataaag	ctgtgtgtcc	tttgtcttgg	gagacaaagc	ccacagcagg
tgggtggttg	gtggtggcag	ctcagtgaca	ggagagggtt	ttttgcctgt	tttttttggt
gttttttttt	tttaagtaag	gtgttctttt	ttcttagtaa	aatctctact	ggactgtatg
ttttgacagg	tcagaaacat	ttcttcaaaa	gaagaacctt	ttggaaactg	tacagccctt
ttctttcatt	ccctttttgc	ttctgtgtgc	aatgcctttg	gttctgattg	cattatggaa
aacgttgatc	ggaacttgag	gttttttatt	atagtgtggc	ttgaaagctt	ggatagctgt
tgttacatga	gataccttat	taagtttagg	ccagcttgat	gctttatttt	ttttccctttg
aagtagtgag	cgttctctgg	tttttttctt	ttgaaactgg	cgaggcttag	atttttctaa
tgggattttt	tacctgatga	tctagtgtga	tacccaaatg	cttgtaaagt	ttttcctagt
taacatggtg	ataacttcgg	atttacatgt	tgtatatact	tgtcatctgt	gtttctagta
aaaatatatg	gcatttatag	aaatacgtaa	ttcctgattt	cctttttttt	ttatctctat
gctctgtgtg	tacagggtcaa	acagacttca	ctcctatttt	tatttataga	attttatatg
cagtcgtctg	ttggttcttg	tgttgtaagg	atacagcctt	aaatttctca	gagcgaatgct

cagtaaggcg	ggttgtcaca	tgggttcaaa	tgtaaaacgg	gcacgtttgc	tgctgccttc
ccagatccag	gacactaaac	tgcttctgca	actgagggtat	aaatcgcttc	agatcccagg
aagtgtagat	ccacgtgcat	attctttaaag	aagaatgaat	actttctaaa	atatgttggc
ataggaagca	agctgcatgg	atatttttgg	gacttaaatt	attttggtaa	cggagtgcac
aggtttttaa	cacagttgca	gcatgctaac	gagtcacagc	atztatgcag	aagtgatgcc
tggtgcagct	gtttacggca	ctgccttgca	gtgagcattg	cagatagggg	tggggtgctt
tgtgtcgtgt	tgggacacgc	tgccacacag	ccacctcccg	aacatatctc	acctgctggg
tacttttcaa	accatcttag	cagtagtaga	tgagttacta	tgaaacagag	aagttcctca
gttgatatt	ctcatgggat	gtcttttttc	ccatgttggg	caaagtatga	taaagcatct
ctatttgtaa	attatgcact	tgtagttcc	tgaatccttt	ctatagcacc	acttattgca
gcagggtgtag	gctctggtgt	ggcctgtgtc	tgtgcttcaa	tcttttaagc	tt

The invention provides a method of transforming one or more eukaryotic cells by co-transfecting two or more nucleic acid vectors into the cell. These two or more vectors include a first vector containing a gene encoding a desired protein to be expressed by the cell and a promoter controlling the expression of this gene, as well as a second vector containing at least one chromatin element such as a MAR element (*e.g.*, a chicken lysozyme MAR element). The nucleic acid sequences of SEQ ID NOs 1-5 are useful as MAR elements of the present invention. In various embodiments, the first and second vectors are integrated into the host cell's chromosomal DNA. Those skilled in the art will recognize that any means of transfection can be used in accordance with the methods disclosed herein. In some embodiments, the first vector contains a single chromatin element (*e.g.*, a MAR element). In some other embodiments, the invention provides a method of transforming one or more eukaryotic cells by co-transfecting three or more nucleic acid vectors into the cell. Additionally transfected vectors may include, *e.g.*, genes encoding for structural or regulatory proteins, or selection genes.

In some embodiments, enhancer elements are optionally included in one or more of the vectors of the invention.

The ratio of the first and second vectors may be adapted as required for the use of specific cell types, and is routine experimentation to one of ordinary skill in the art. A non-limiting exemplary range of molar ratios of the first vector to second vector is between about 1:2 and about 1:10. However, other ratios are also envisioned by this invention, including 2:1, 1:1, 1:20, 1:50, 1:100 and 1:1000 or more.

The present invention also envisions the use of butyrate to modulate (*e.g.*, increase) transgene expression (see, *e.g.*, Example 6, *infra*). Butyrate may be added to the cell prior to, concomitant with, or following addition of the nucleic acid vectors. One skilled in the art would easily determine the most advantageous time and concentration of butyrate for the cell line being transfected. For example, butyrate may be added in a concentration of about 0.1

mM to about 1 M. Preferably, in an amount of about 1-500 mM, 1-250 mM, 1-100 mM, 1-75 mM, 1-50 mM, 1-25 mM, 1-20 mM, 1-15 mM, 1-14 mM, 1-13 mM, 1-12 mM, 1-11 mM or 1-10 mM. Those skilled in the art will recognize that the specific effect(s) of butyrate depend upon the cell type used in the co-transfection, and that the addition of butyrate may or may not affect the proliferation or differentiation of the transfected cells. Butyrate may be added in the form of sodium butyrate or any other compound known to those skilled in the art.

The invention further encompasses the co-transfection of the eukaryotic cell with one or more unlinked nucleic acid vectors in addition to the first vector containing a gene encoding a desired protein to be expressed by the cell, the expression of this gene is controlled by a promoter, and the second vector containing at least one chromatin element (*e.g.*, a chicken lysozyme MAR element). The additional vector or vectors may encode for selection genes or product genes or both. In such embodiments where three unlinked vectors are co-transfected, the ratio of first, second and third vectors may be adapted as required for the use of specific cell types. Determination of the ratio of these vectors is a matter of routine experimentation to one of ordinary skill in the art. For example, a non-limiting molar ratio range of the first, second and third vectors is between about 1:1.75:5.5 and about 1:1.75:11. Other ratios including 1:2:20, 1:2:50, 1:2:100 or 1:2:1000 or more, are also envisioned by this invention.

Also provided are methods to select a transfected eukaryotic cell that expresses a desired level of a gene encoding for a desired protein. In certain instances, these cells may produce larger quantities of the desired protein (such as for therapeutic protein production and purification) or smaller quantities of protein (such as for functional analysis). In a preferred embodiment, the expression of a gene in a first cell co-transfected with a first vector containing a gene encoding a desired protein to be expressed by the cell, and a second vector containing at least one chromatin element such as a MAR element, is compared with the expression of the gene in a second cell transfected with only the first vector, and the first cell is selected if the level of expression of the first gene is different between the first and the second cells. This method is useful to select those transfected cells in which the presence of the second vector containing the MAR element is advantageous (*e.g.*, causes an increase of) to the expression of the desired gene.

The present invention also encompasses cell transfection compositions, which can be used to increase the expression of a gene that encodes a desired protein in a cell. In one embodiment, this cell transfection composition includes a vector containing at least one MAR element (*e.g.*, a chicken lysozyme MAR element). In another embodiment, the cell

transfection composition may include a first vector containing a gene encoding a desired protein or a portion thereof to be expressed by the cell, and a second vector containing at least one chromatin element such as a MAR element. The cell transfection composition may also additionally contain butyrate, for example in a concentration of about 10 mM, about 100 mM or about 1 M butyrate.

The present invention also encompasses a eukaryotic cell that has been co-transfected, containing a first vector having a first promoter and a first gene encoding a desired gene or a portion thereof, and a second vector comprising a MAR element. As an embodiment of the invention, the first and/or the second vectors are integrated into the chromosomal DNA of the eukaryotic cell. The co-transfected eukaryotic cell may be a butyrate-treated cell. The invention also encompasses a eukaryotic cell that has been co-transfected, containing two or more vectors, a first vector having a first promoter, a first gene encoding a desired gene or a portion thereof and a MAR element, and a second vector comprising at least one MAR element. The invention further encompasses a eukaryotic cell that has been co-transfected, containing three or more vectors, a first vector having a first promoter and a first gene encoding a desired gene or a portion thereof, a second vector comprising at least one MAR element, and a third vector comprising a second promoter and a second gene encoding a desired gene or a portion thereof. In some embodiments of the invention, the second gene encodes for a selection gene or a gene encoding a detectable gene product (*e.g.*, a fluorescent protein such as green fluorescent protein, or a luminescent protein such as luciferase).

The present invention provides kits for transfecting eukaryotic cells. For example, the kit can have in one or more containers, two or more nucleic acid vectors, the first vector having a promoter and a heterologous gene coding for a desired protein, and the second vector having at least one MAR element, and directions for use thereof. In an embodiment, the invention provides kits, containing in one or more containers, one or more eukaryotic cells containing two or more nucleic acid vectors, the first vector having a promoter, a heterologous gene coding for a desired protein and a MAR element, and the second vector having one or more MAR elements. In an embodiment, the kit additionally comprises butyrate. The vectors of the kits are provided in ratios that one skilled in the art would be able to use on a cell line under study with minimal experimentation.

EXAMPLES

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

5 Example 1: General Materials and Methods

Plasmid construction. The luciferase expression vectors used to test the chromatin elements are all based on pGL3-Control (Promega). This plasmid contains an SV40 promoter in front of a modified firefly luciferase cDNA, followed by the SV40 late poly(A) signal and the SV40 enhancer. The *Drosophila melanogaster* elements come from the p7, p83 and p1314
10 plasmids (Poljak et al., 1994). The 1.8 kb SalI scs (special chromatin structure) BE fragment comes from p83, as well as the 960 bp BamHI-XhoI heat shock 87A locus SAR (hsp SAR). The 500 bp BamHI scs' BE fragment is derived from p7, whereas the 657 bp EcoRI-HinfI histone SAR (his SAR) comes from p1314.

Combinations of these elements were first cloned into the BamHI SalI sites of pGL3-
15 Control. The scs' BE and hsp SAR were cloned as BamHI-EcoRI and EcoRI-SalI fragments respectively, giving pMZ61. Similarly, the BamHI-EcoRI scs' BE fragment and EcoRI-SalI his SAR fragment were inserted to give pMZ62, and the BamHI-EcoRI his SAR and EcoRI-SalI scs' BE were introduced to yield pMZ63. Chromatin elements were then cloned in sites upstream of the luciferase expression cassette. Construct pMZ67-1 was obtained by cloning
20 the KpnI-BamHI hsp SAR and BamHI scs BE fragments into the KpnI BglII sites of pMZ61, whereas pMZ70-1 resulted from cloning the same fragments into pMZ62. Vector pMZ71 was constructed by introducing the KpnI-EcoRI his SAR and EcoRI-BamHI scs' BE fragments in the KpnI BglII sites of pMZ61, whereas pMZ68 resulted from cloning the same fragments in pMZ62. Lastly, pMZ69 was obtained by cloning the XbaI-EcoRI scs' BE and EcoRI-BamHI
25 his SAR fragments in the NheI BglII sites of pMZ63. The 2.95 kb BamHI-XbaI chicken lysozyme MAR (lys MAR) fragment (Phi-Van and Strätling, 1988) is from pUC-B-1-X1 (Wolf Strätling). It was first cloned into the BamHI SalI sites of pGL3-Control, giving pMZ50. Construct pMZ52 was obtained by inserting a second MAR as a KpnI-XbaI fragment into the KpnI NheI sites of pMZ50. The mouse T-cell receptor α LCR 6kb
30 subregion (Ortiz et al., 1997) originated from p3'LCR-72 (Astar Winoto). It was cloned into the SalI and filled-in BamHI sites of pGL3-Control as a SalI and filled-in EcoRI fragment, giving pMZ74. The 2 kb NheI fragment from S1 LIP (Ueli Schibler) presumably

encompasses the rat LAP LCR (Talbot et al., 1994). It was cloned in both orientations as a KpnI-filled in NotI fragment into the KpnI SmaI sites of pGL3-Control to give pMZ44 and pMZ45.

The immunoglobulin expression vectors, pMZ57 and pMZ36, are identical to those described elsewhere (Miescher et al.), except that the human cytomegalovirus MIE promoter/enhancer drives light and heavy chain expression. The plasmids for the regulated expression system, pEF1-TetRNLS-TR450W, pPGK-TetRNLS-TR450W, pSV-TetRNLS-KoxW, pVG-GTTI-Luc+, p5xGTTI-GVP and p5xGTTI-mEpoires β Geo have previously been described (Imhof et al., 2000) All plasmids were constructed using standard techniques.

- 10 CHO cell culture and transfection. The CHO DG44 cell line (Urlaub et al., 1983) was cultivated in DMEM:F12 (Gibco-BRL) supplemented with HT (Gibco-BRL) and either 2 or 10 % FBS (Gibco-BRL). Pools of stable CHO cells expressing luciferase were obtained by transfection with polyethyleneimine (PEI) (Boussif et al., 1995). Cells were seeded in 6-well plates at 500-750 000 cells/well and allowed to attach overnight. Equimolar amounts of PvuI-
- 15 linearized test constructs, corresponding to 2 - 3 μ g pGL3-Control, were co-transfected with pSV2neo (CLONTECH Laboratories, Inc.) in a 10:1 molar ratio, with transfection mixes brought to a total of 10 μ g with either pUC19 or pBluescript. Plasmid DNA was diluted in 150 mM NaCl, and an equal volume of 150 mM NaCl solution containing 35 μ l 10 mM PEI25 (Fluka) was added. Following a 15 min. incubation at room temperature, the
- 20 transfection mix was added to the cells. The medium was either replaced or supplemented with fresh medium after 4 hours. After 48 hours, cells were washed with PBS, trypsinized and replated in medium supplemented with 700 μ g/ml geneticin (G-418 sulphate, Gibco-BRL). Subsequent medium changes were carried out with medium supplemented with 500 μ g/ml geneticin, with pools of clones assayed after 13 and 15 days of selection. Individual
- 25 clones expressing luciferase were picked after 12 - 14 days of selection, and maintained in selective medium prior to analysis.

- Stable CHO clones expressing human anti-Rhesus D IgG1 antibody were obtained by co-transfecting the light chain vector pMZ57, the heavy chain vector pMZ36 and either the MAR-bearing plasmid pUC-B-1-X1, or pUC18 as a control. A total of 2.5 μ g of DNA per
- 30 well, with either a 1:1.75:5.5 or 1:1.75:11 molar ratio of pMZ57:pMZ36:pUC-B-1-X1 was used, corresponding to a 2:1 and 4:1 molar ratio of MAR: antibody plasmids respectively. Cells were seeded in a 12-well plate at 140 000 cells/well, 18 h prior to transfection using an

optimized calcium-phosphate precipitation method (Jordan et al., 1996). A glycerol shock (10% glycerol in PBS 1X) was applied 3 hours after transfection, and cells were maintained for 2 days under non selective conditions in medium supplemented with 8% FCS. Selection in MEM (GHT-) medium (Sigma), supplemented with 100 μ M L-Proline, 5% dialyzed fetal bovine serum (Gibco-BRL) and buffered with 10 mM HEPES, was carried out upon replating the cells in 10 cm dishes. Colonies arose after 10-14 days, and stable clones were transferred to 24-well plates. After 8 days, culture supernatants were diluted two- and ten-fold, and antibody concentration determined by ELISA.

C2C12 cell culture and transfection. The C2C12 cell line was cultured in DMEM (Gibco-BRL) supplemented with 10 % FCS. Stable C2C12 clones expressing the repressor were obtained by co-transfection using Lipofectin™ (Gibco-BRL) of TK-Hyg, one of the repressor expression plasmids, pEF1-TetRNLS-TR450W, pPGK-TetRNLS-TR450W, pSV-TetRNLS-KoxW, and the MAR plasmid pUC-B-1-X1, in a 1:4 molar ratio. Clones were picked after selection for 9 days with 200 μ g/ml hygromycin B (Gibco-BRL). Transient transfection with pVG-GTTI-Luc+, and pCMV β gal (MacGregor and Caskey, 1989) as an internal standard for transfection efficiency, was performed in triplicate essentially as described previously (Imhof et al., 2000). The medium, with or without 100 ng/ml doxycycline hydrochloride (Sigma), was changed every 24 hours, and cells were harvested 48 hours post-transfection. The pool of clones with the pEF1-TetRNLS-TR450W repressor was co-transfected with the activator expression plasmid p5xGTTI-GVP, the reporter plasmid p5xGTTI-mEpoires β Geo and the MAR plasmid pUC-B1-X-1. After selection with 500 μ g/ml geneticin, flow cytometric analysis of the pool of clones using fluorescein di- β -D galactopyranoside (Molecular Probes) was performed according to the manufacturer. Cells with an intermediate expression of β -galactosidase were sorted, and these clones were expanded in medium without doxycycline. These clones were screened for induction in the presence of 100 ng/ml doxycycline hydrochloride, and those expressing β -galactosidase were selected. Following culture in medium without doxycycline hydrochloride, the clones were assayed in the presence and absence of doxycycline.

Cell lysates and reporter assays. Cell extracts were prepared as follows for luciferase and protein measurements. Cells were washed with PBS and incubated with 100 μ l lysis buffer (25 mM Tris-phosphate, pH 7.8, 2 mM DTT, 2 mM CDTA, 10% glycerol, 0.5% Triton X-100) for 20 min at room temperature. Luciferase measurements were carried out with 20 μ l of

extract in white 96 well plates. The constant glow type assay was performed in an EG&G Berthold Microplate 96V luminometer, using the reagents described in the Luciferase Assay Reagent protocol (Promega). For each well, 100 μ l substrate solution was added by injection. After a delay of 2 sec light emission was measured for 2 seconds. Colorimetric determination of β -galactosidase activity was performed as previously described (Imhof et al., 2000). Colorimetric determination of protein content was performed by adding a mix of 155 μ l water and 40 μ l protein assay dye reagent concentrate (BioRad) to 5 μ l cell extract in 96 well plates and measuring the absorbance at 595 nm (Spectramax 340, Molecular Devices). All absorbance values were within the linear range of a standard curve established with BSA. Luciferase values were normalized with respect to protein content for CHO clones. For the C2C12 clones, the luciferase values were normalized with respect to β -galactosidase activity, and the β -galactosidase values with the protein content. Human immunoglobulin secreted into the medium was measured by a sandwich ELISA, with unconjugated goat anti-human kappa light chain antibody and alkaline phosphatase-conjugated goat anti-human IgG γ as capture and detection antibodies respectively (BioSource).

Southern and plasmid rescue analyses. Genomic DNA for Southern analysis was isolated with Nucleospin C+T (Macherey & Nagel, Germany) according to the manufacturer's instructions. Aliquots (4 μ g) were digested to completion with EcoRI, separated by agarose gel electrophoresis, and blotted onto Hybond N+ membranes (Amersham, England). The full-length MAR probe was isolated from pUC-B-1-X1 as a BamHI-XbaI fragment. Radiolabeling was performed with HighPrime (Roche, Switzerland).

For the plasmid rescue experiments, episomal DNA was isolated from stable cell lines generated by the transfection of the IgG1 and MAR vectors, from untransfected CHO DG44 cells, and from cells transiently transfected with pUC-B-1-X1 one week before DNA isolation. Cells were counted, lysed in alkaline conditions and plasmids purified with the Nucleospin kit (Macherey & Nagel, Germany). Competent *E. coli* cells (Electro ax DH10B, Gibco) were electroporated with the plasmid-extract from approximately 10^5 cells with a BioRad Gene Pulser unit according to the cell supplier's instructions. Transformants were selected on LB plates containing 100 μ g/ml ampicillin.

Construction of cis MAR expression vectors. The cis MAR SV40 IgG-kappa and gamma vectors were created by cloning the BamHI-Xba I MAR fragment from pUC-B1-X1 in

plasmids pMZ59 and pMZ37, respectively, linearized with EcoRI and BamHI. The XbaI site of the MAR fragment and EcoRI site of pMZ59 and pMZ37 were first blunted with Pfu. To synthesize the cis MAR CMV IgG kappa and gamma vectors, pMZ57 and pMZ36 were first digested with AvaI and KpnI, respectively, blunted with T4DNA polymerase and then cut with BamHI. The XbaI filled BamHI MAR fragment described above was cloned in the latter vectors.

Example 2: Chromatin elements and stable transgene expression in CHO cells

The use of structural chromatin components to overcome silencing of stably integrated genes by the surrounding chromosomal environment will prove particularly useful in biotechnology. Unfortunately, fully characterized chromatin elements in higher eukaryotes are rare. Moreover, most of these have not been tested with a heterologous promoter in heterologous cells. Elements which counteract the effect of neighboring chromatin structure on stable transgene expression are expected to raise the average transgene expression in pools of stable clones, where the effects of different integration sites and the number of active copies become averaged.

Single chromatin elements or combinations of chromatin elements were cloned on either, or both sides, of the luciferase expression unit of pGL3-Control as depicted in Fig. 1. Various combinations of *Drosophila melanogaster* SAR and BE elements were tested flanking the reporter expression cassette. These elements had previously been shown to stimulate stable reporter gene expression in HeLa and L cells (Poljak et al., 1994). The chicken lysozyme 5' MAR element (lys MAR), or 'A-element' was cloned flanking the luciferase expression cassette, in a configuration previously shown to confer elevated expression in chicken promacrophage and rat fibroblast cells (Phi-Van et al., 1990; Stief et al., 1989). The mouse T-cell receptor α LCR (TCR α LCR) and the rat liver activated protein LCR (LAP LCR) have both been shown to direct high-level expression in multiple tissues in transgenic mice (Ortiz et al., 1997; Talbot et al., 1994). The position and orientation of the two LCRs with respect to the transgene promoter was as in their original locus.

The chromatin elements had little or no effect on transient expression levels where chromatin structure does not come into play. Pools of stably transfected CHO cells were analyzed for transgene expression (Fig. 1). A modest 2- to 4-fold increase in expression levels was seen for all combinations tested of the *Drosophila* SAR and BE elements, as well as for the two LCRs tested. The only element tested showing an important increase in stable

reporter expression was the chicken lysozyme 5' MAR, which gave a 20-fold increase in luciferase expression as compared to the pGL3-Control construct. In accordance with previous results in chicken cells (Stief et al., 1989), the orientation of the two MAR elements flanking the reporter expression cassette had no effect on transgene expression. Following this initial screening of the chromatin elements in CHO cells, attention was focused on the use of the chicken lysozyme MAR for its usefulness in stable cell line development.

Example 3: Co-transfection of the MAR improves stable transgene expression.

An alternative strategy to cloning the MAR element into the reporter expression vector is that of co-transfecting a MAR element-containing plasmid with the transgene expression vector. The observation that transfection with multiple plasmids appears to result in co-integration of multiple plasmid copies at the same chromosomal site (Wurm et al., 1992) suggests that the MAR element does not need to be physically linked with the transgene expression cassette at the time of transfection. However, the organization of the various integrated plasmids, and how these may recombine to generate the integrated DNA, is not known. A significant increase in stable transgene expression level is observed when MAR elements flank both sides of the reporter gene expression cassette, suggesting that a precise order of the genetic elements is required. While MAR orientation does not affect stable expression, a particular arrangement with defined spacing may be required. Nevertheless, whether co-transfection of the MAR and the plasmid bearing the reporter expression cassette may also result in enhanced stable transgene expression was determined.

The pGL3-Control reporter was co-transfected with increasing amounts of plasmid pUC-B-1-X1 bearing the chicken lysozyme MAR. Fig. 2 shows the luciferase activity in pools of CHO clones, including results for constructs pMZ50 and pMZ52 with one and two MARs adjacent to the luciferase transcription unit respectively. Comparison of stable expression with pMZ50 and pMZ52 shows that two flanking MARs have a greater effect than a single MAR, when present on the expression plasmid itself. On the other hand, increasing the ratio of MAR plasmid to reporter construct from a molar ratio of 1:1 to 4:1 also results in increased stable expression. Co-transfection of the reporter construct with two MARs yields the same stable expression as the pMZ50 construct with one MAR. Although co-transfection with MARs does not result in stable luciferase expression levels comparable to those obtained with the pMZ52 construct with two flanking MARs, it may also provide an alternative means to enhance stable transgene expression.

Example 4. The MAR increases the prevalence of top producing clones

While increased expression in pools of stable clones is indicative of an overall positive effect of the chicken lysozyme MAR on transgene expression, it does not provide information as to the probability of isolating a high producer clone. To address this issue,
5 individual colonies were isolated and the level of expression of the transgene was measured.

CHO cells were transfected with luciferase expression vectors containing none, one, or two MARs, and fifteen individual colonies were randomly isolated and analyzed for each construct. The level of stable luciferase expression of individual colonies, ranked from lowest to highest, is shown in Fig. 3A. Consistent with the results obtained with pools of stable
10 clones, the average expression level of the clones analyzed increases with the number of MARs present on the construct. More importantly, having MARs on the expression construct clearly increases the prevalence of top producing clones. Furthermore, the expression level of the most productive clones is higher for constructs bearing MARs. Thus fewer clones need to be picked and analyzed to identify a high-level production clone when MARs are present on
15 the expression plasmid.

A more complex situation occurs with the stable production of a protein composed of multiple subunits expressed from separate plasmids. Instead of cloning the MAR element into each separate vector, whether a simple co-transfection of MARs can also result in improved stable expression levels was examined. To do so, expression vectors for the light and heavy
20 chain of the medically relevant human anti-Rhesus D antibody (Miescher et al., in press) were used. Light and heavy chain expression vectors containing introns, were transfected along with either the pUC-B-1-X1 MAR-bearing plasmid or its pUC backbone as a control. Individual stable CHO colonies were picked and analyzed for antibody expression (Fig. 3B). While few colonies express antibody in the control with pUC18, the proportion of colonies
25 expressing detectable amounts of anti-Rhesus D antibody increases with increasing amounts of MAR.

As seen with the MAR-bearing luciferase constructs, the level of antibody expression of the most productive clones is markedly higher for the MAR colonies than for the controls. Thus the chicken lysozyme MAR increases both the proportion of top producing clones and
30 their expression levels. This is true when the MAR is present on the expression construct, as well as when the MAR is co-transfected with one or more expression constructs. Practically, this means that complex cloning strategies can be bypassed by co-transfection with the MAR element, resulting in the same advantages for stable cell line development. Most importantly,

these advantages are also seen upon co-transfection of a MAR element-bearing plasmid with several expression vectors.

In order to confirm that the MAR element has been integrated into the host cell genome, four randomly chosen antibody-expressing clones were analysed by Southern blotting (Fig. 3C). Two fragments, a 1.8 kb MAR fragment and a fragment of variable size corresponding to the remainder of the MAR, are present in all clones and absent in the parent CHO DG44 cell line. Both the light and heavy chain vectors also integrated. A MAR element has recently been shown to enable episomal replication of SV40 ori-containing transfected vectors in CHO cells (Piechaczek et al., 1999). No 3.8 kb band corresponding to pUC-B-1-X1 replicating episomally in CHO cells is detected in the Southern blots. Plasmid rescue experiments were carried out to determine whether the plasmid is present episomally at low copy numbers. Control CHO transient transfections with one copy of the MAR-bearing plasmid pUC-B-1-X1 per cell yielded over 200 colonies. In contrast, the four clones and DG44 yielded a background of up to 4 colonies containing DNA unrelated to the transfected plasmids. Together, these experiments provide evidence that the transfected MAR is not replicating episomally but is integrated into the chromosome of the stable clones.

Example 5. Co-transfection of the MAR to establish a stable regulated expression system

Most currently used regulated gene-expression systems are based on multiple components. In such systems, the stable expression of individual regulatory elements is critical to the control of the expression of the transgene. To date, chromatin elements have rarely been employed in such systems and their use has essentially been restricted to inserting such elements so as to flank the transgene construct (Wang et al., 1997; Wells et al., 1999). It was examined whether a stable regulated expression system can be obtained by co-transfection of the MAR with the components of a regulated expression system (Imhof et al., 2000). This tetracycline-based switch system involves chimeric repressor and activator proteins acting to control transgene transcription.

In a first step, the repressor protein expression vector is stably transfected. Initially, transfection of the vector alone yielded clones in which transgene expression could not be regulated. These clones exhibited unstable repressor protein expression, especially after removal of selective pressure. The three repressor protein expression vectors with the chicken lysozyme 5' MAR plasmid were then separately transfected. The results of a screen of 24 clones, obtained by lipofection, for their ability to induce luciferase expression upon addition of doxycycline is shown in Fig. 4A. A majority of the clones (21 out of 24) show regulated

transgene expression, with several exhibiting over 400-fold induction of reporter expression in the presence of doxycycline. Furthermore, regulated gene expression was obtained irrespective of the method of transfection and of the promoter driving repressor protein expression.

5 In a second step, the activator and reporter constructs are stably transfected into clones expressing the repressor. A pool of clones stably expressing the repressor protein, and from which clones 1 through 8 in Fig. 4A were isolated, was used to this end. The activator and reporter constructs were stably co-transfected with the chicken lysozyme 5' MAR plasmid, and individual cell clones expressing an intermediate level of β -galactosidase were
10 isolated by FACS sorting. These were screened for induction in the presence of doxycycline, and the resulting ten clones tested for the regulation of β -galactosidase expression in the absence and presence of doxycycline after 3 days (Fig. 4B). Five of these clones show regulated expression of β -galactosidase, with an induction ranging from 17- to 45-fold in the presence of doxycycline. Regulated expression of the second transgene, mouse
15 erythropoietin, is also observed (Imhof et al., 2000). Hence cell lines showing regulated expression were obtained by co-transfection of the chicken lysozyme MAR with the elements of the expression system.

20 Example 6. MAR- and Butyrate-mediated increased level of protein production in transiently transfected CHO cells

A dramatic increase in transgene expression occurs when the chicken 5'-lysozyme MAR is combined with the addition of sodium butyrate to the cell culture medium. Without wishing to be bound by theory, this effect may result from an increased efficiency of DNA
25 transfection, alterations in cell proliferation and/or differentiation, and/or other cellular mechanisms. Butyrate has been used in transient or stable transfections (Gorman et al., 1983 Nucl. Acids Res. 11:7631; Reeves et al., 1985, Nuci. Acids Res. 13:3599).

Vectors: Plasmids encoding anti-RhesusD IgG kappa and gamma chains, pMZ59 and
30 pMZ37, are as previously described for pMZ58 and pMZ36, respectively, except that they contain the SV40 early promoter instead of the CMV promoter (see Example 1). pMZ126 and pMZ127 derive from pMZ59 and pMZ37, but contain in addition one MAR element in cis upstream from the SV40 promoter. pMZ126 and pMZ127 were constructed as follows:

pUCB1X1 was digested with XbaI, blunt-ended with Pfu DNA polymerase, digested with BamHI and subcloned directionally in pMZ59 and pMZ37, respectively, that had been first cleaved with EcoRI, blunt-ended with Pfu DNA polymerase, and then digested with BamHI.

- 5 Cell culture and transfection: CHO cells were grown as described in Example 1. For transfection, cells were treated as described previously with the following modification: 24 h. after addition of 1 ml of DMEM supplemented with 10% FBS (Gibco, Life Technologies) to each well, 26 μ l of 500 mM NaButyrate pH 6,9 in PBS was added to half of the wells where indicated in the figure legend. Aliquots of 2 μ l were taken at 24 h. intervals and transferred in
10 248 μ l of blocking solution in a 96-wells plate. IgG titer was determined as described previously by double sandwich ELISA.

Example 7. MAR element multimerization.

- 15 The MAR elements of the invention include fragments of MAR elements, such as fragments of SEQ ID NO:1. Figure 7 demonstrates that four copies of the MAR fragment F (pF4L) display similar expression as those obtained with the longer, natural MAR sequences. Other fragments display lower (K, B) or no (G) expression. When two distinct MAR element fragments are combined, in PK4F4L or in pB4K4L, higher expression than the full length
20 MAR element (SEQ ID NO: 1) is obtained. Thus, particular combinations of MAR element fragments are preferred in order to modulate transgene expression, depending on whether a small size or maximal expression is desired.

Materials and methods:

- 25 Construction of pLuc-based plasmids (SV40 promoter-based luciferase gene construct) :

The various MAR fragments (*i.e.* B, K, F and G) were amplified by polymerase chain reaction using pUC-BI-XI as template with specific primer sets that introduced a BglII and a BamHI site in 5'- and 3'-end, respectively. After release of the latter restriction sites, the
30 fragments were self-ligated in presence of BglII and BamHI. The dimer- and tetramer-repeats in direct orientation were cloned between the BglII-BamHI sites of pGL3-Control (Promega). To construct the pLuc-based plasmids, the various tetramers were excised as BglII-BamHI fragments and subcloned into plasmid pGL3-Control at the BglII site. For pF4G4L, pK4G4L and pB4G4L, the F4, K4 and B4 fragments were cloned into the BglII site of plasmid pG4L,

respectively. The plasmids pK4F4L and pB4F4L were constructed by cloning K4 and B4 in pF4L and pB4K4L was generated by cloning B4 into the BglII site of pK4L.

Cell culture and stable gene transfer:

5 CHO DG44 cells were grown as described (See *supra*). The above pLuc-derivatives and pGL3-Control were transfected in parallel in order to create the recipient cell lines for expression studies of MAR fragments vectors and control vectors. For transfection, cells were seeded in 24-well plates at 1.3 E5 cell/well and allowed to attach for 16H. After washing with PBS, cells were transfected in triplicate with mixes in a final volume of 81 µl OptiMEM
10 (Gibco, Life Sciences). Typically, the mixes contained 0.327 pmol of MAR-derivative plasmids and pGL3-Control and 23,4 fmol of pSVneo. In a polystyrene tube, 77 µl OptiMEM were combined with 4 µl of LipofectAMIN2000 (Gibco, Life Sciences) per triplicate and incubated for 5 min. Subsequently, the DNA and Lipofectamin2000 mixes were combined in a polystyrene tube. After 15 min at room temperature, the mixes were supplemented with 1
15 ml OptiMEM per triplicate and 300 µl of these mixes were aliquoted into each well. Cells were exposed to the transfection mixes for 3H. Thereafter, 1ml of DMEM supplemented with 10%FBS (Gibco, Life Sciences) was added to each well. Cells were passaged 48H post-transfection and the triplicates pooled into T-75 containing 14 ml of medium supplemented with 750 µg G-418. The medium was replaced every 4 days. Cells were passaged two weeks
20 post-transfection.

Extract preparation and enzymatic measurements:

Triplicate 250 µl samples of cell suspension were harvested by centrifugation, washed with PBS, and incubated with 100 µl lysis buffer for 20 min at room temperature. 20 µl of extracts
25 were transferred to a flat bottom 96 well for subsequent luciferase measurement. 5 µl of extracts were used for protein determination by Bradford.

Relative light units were calculated by normalizing luciferase for Bradford measurement. Data points represent the average of the triplicate of two independent transfection experiments.

30

Sequences of MAR fragments :

1. Fragment B (MAR region : bp 374-765)

BglII-

GATCTGcaaattgcttaacagtctcctaaaggctgaaaaaagggaacccatgaaagctaaaagtatgcagttattcaag
 tataacatctaaaaatgatgaaacgatccctaaaggtagagattaactaagtacttctgctgaaaaatgtattaaaatccgcagtt
 gctaggataccatcttacctgttgagaaatacaggtctccggcaacgcaacattcagcagactctttggcctgctggaatca
 5 ggaaactgcttactatatacacatataaaatcctttggagtgggcattctgagagacatccatttcctgacatttgcagtgcaa
 ctctgcattccaactcagacaagctcccatgctgtatttcaaagccatttctgaatagttGGATC (SEQ ID NO:
 6)

-*BamHI*

- 10 2. Fragment K (MAR region : bp 840-1230)

Bgl II-

GATCTAagtcagcagcgctggtaatcttcataaaaatgtaactgtttccaaatagggaatgtatttcactgtaaaacacct
 ggtcctttttatattacttttttttttaaggacacctgcactaatttgcaatcacttgatittataaaagcacacgcactcctcattt
 tcttacatttgaagatcagcagaatgtctcttcataatgaataatcatatgcacagtttataatattttctattacaaaatacagta
 15 cacaagagggtgaggccaaagtctattacttgaatatattccaaagtgtcagcactgggggtgtaaaattacattacatggat
 gaataggcgggaattctttacaactgaaatgctcgatttGGATC (SEQ ID NO: 7)

-*BamHI*

- 20 3. Fragment F (MAR region : bp 1975-2421)

Bgl II-

GATCTAcaacacaagaaccaacgacagactgcataaaaaattctataaaaaaataaggagtgaagtcgtttgacctgt
 acacacagagcatagagataaaaaaaaaggaaatcaggaattacgtatttctataaatgcatatattttactagaaacaca
 gatgacaagtatatacaacatgtaaatccgaagttaacatgtaactaggaacattacaagcatttgggtatgcaact
 agatcatcaggtaaaaaatcccattagaaaaatctaagcctcgccagtttcaaaggaaaaaaaccagagaaacgctcactact
 25 tcaaaggaaaaaaataaagcatcaagctggcctaaacttaataagggtatctcatgtaacaacagctatccaagctttcaagc
 cacactataaaaaaacctcaagttccgatcaacgttgatcccgGGATC (SEQ ID NO: 8)

-*BamHI*

- 30 4. Fragment G (MAR region : bp 2485-2906)

BglII-

GATCTgggctgtacagtttccaaaagggttcttctttgaagaaatgtttctgacctgtcaaaacatacagtcagtagaat
 tttactaagaaaaagaacaccttacttaaaaaaaacaacaaaaaaacaggcaaaaaaacctctcctgtcactgag
 ctgccaccaccaaccaccacctgctgtgggctttgtctccaagacaaaggacacacagccttatccaatattcaacatta
 ctataaaaaacgctgatcagaagaataaccaagtatttctcagagactgttatcccttcacgtggcaacaagagatgaaata
 35 caacagagtgaatatcaaagaaggcggcaggagccaccgtggcaccatcaccgggcagtgagtgcccaactgccgttt
 tctgagcagcataggaaggATC-*BamHI* (SEQ ID NO:9)

References:

- 40 Agarwal, M., Austin, T., Morel, F., Chen, J., Bohnlein, E., and Plavec, I. (1998). Scaffold
 attachment region-mediated enhancement of retroviral vector expression in primary T cells. J
 Virol 72, 3720-3728.
- Allen, G., Hall, G. J., Michalowski, S., Newman, W., Spiker, S., Weissinger, A., and
 45 Thompson, W. (1996). High-level transgene expression in plant cells: effects of a strong
 scaffold attachment region from tobacco. Plant Cell 8, 899-913.

- Bell, A., and Felsenfeld, G. (1999). Stopped at the border: boundaries and insulators. *Curr Opin Genet Dev* 9, 191-198.
- 5 Bi, X., and Broach, J. (1999). UASrpg can function as a heterochromatin boundary element in yeast. *Genes Dev* 13, 1089-1101.
- Bode, J., Benham, C., Knopp, A., and Mielke, C. (2000). Transcriptional augmentation: modulation of gene expression by scaffold/matrix-attached regions (S/MAR elements). *Crit*
10 *Rev Eukaryot Gene Expr* 10, 73-90.
- Bode, J., Schlake, T., Rios-Ramirez, M., Mielke, C., Stengert, M., Kay, V., and Klehr-Wirth, D. (1995). Scaffold/matrix-attached regions: structural properties creating transcriptionally active loci. In *Structural and Functional Organization of the Nuclear Matrix*, R. Berezney and
15 K. Jeon, eds. (San Diego: Academic Press, Inc.), pp. 389-454.
- Boussif, O., Lezoualc'h, F., Zanta, M., Mergny, M., Scherman, D., Demeneix, B., and Behr, J.-P. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. *Proc Natl Acad Sci U S A* 92, 7297-7301.
- 20 Castilla, J., Pintado, B., Sola, I., Sanchez-Morgado, J., and Enjuanes, L. (1998). Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk. *Nat Biotechnol* 16, 349-354.
- 25 Cuvier, O., Hart, C., and Laemmli, U. (1998). Identification of a class of chromatin boundary elements. *Mol Cell Biol* 18, 7478-7486.
- Fussenegger, M., Bailey, J., Hauser, H., and Mueller, P. (1999). Genetic optimization of recombinant glycoprotein production by mammalian cells. *Trends Biotechnol* 17, 35-42.
- 30 Grosveld, F. (1999). Activation by locus control regions? *Curr Opin Genet Dev* 9, 152-157.
- Hart, C., and Laemmli, U. (1998). Facilitation of chromatin dynamics by SARs. *Curr Opin Genet Dev* 8, 519-525.

- Imhof, M., Chatellard, P., and Mermod, N. (2000). A regulatory network for the efficient control of transgene expression. *J Gene Med* 2, 107-116.
- 5 Jenuwein, T., Forrester, W., Fernandez-Herrero, L., Laible, G., Dull, M., and Grosschedl, R. (1997). Extension of chromatin accessibility by nuclear matrix attachment regions. *Nature* 385, 269-272.
- Jordan, M., Schallhorn, A., and Wurm, F. (1996). Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. 10 *Nucleic Acids Res* 24, 596-601.
- Kalos, M., and Fournier, R. (1995). Position-independent transgene expression mediated by boundary elements from the apolipoprotein B chromatin domain. *Mol Cell Biol* 15, 198-207. 15
- Kaufman, R., and Sharp, P. (1982). Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene. *J Mol Biol* 159, 601-621.
- Klehr, D., Maass, K., and Bode, J. (1991). Scaffold-attached regions from the human 20 interferon β domain can be used to enhance the stable expression of genes under the control of various promoters. *Biochemistry* 30, 1264-1270.
- MacGregor, G., and Caskey, C. (1989). Construction of plasmids that express *E. coli* β -galactosidase in mammalian cells. *Nucleic Acids Res* 17, 2365. 25
- McKnight, R., Shamay, A., Sankaran, L., and Wall, R. (1992). Matrix-attachment regions can impart position-independent regulation of a tissue-specific gene in transgenic mice. *Proc Natl Acad Sci U S A* 89, 6943-6947.
- 30 Miescher, S., Zahn-Zabal, M., Jesus, M. d., Moudry, R., Fisch, I., Vogel, M., Imboden, M., Mermod, N., Stadler, B., Amstutz, H., and Wurm, F. CHO expression of a novel human recombinant IgG1 anti-Rh D antibody isolated by phage panning on bromelain treated rhesus D^{VI+} red blood cells. (in press).

- Neff, T., Shotkoski, F., and Stamatoyannopoulos, G. (1997). Stem cell gene therapy, position effects and chromatin insulators. *Stem Cells* 15, 265-271.
- 5 Ortiz, B., Cado, D., Chen, V., Diaz, P., and Winoto, A. (1997). Adjacent DNA elements dominantly restrict the ubiquitous activity of a novel chromatin-opening region to specific tissues. *EMBO J* 16, 5037-5045.
- Pawliuk, R., Bachelot, T., Raftopoulos, H., Kalberer, C., Humphries, R., Bank, A., and
10 Leboulch, P. (1998). Retroviral vectors aimed at the gene therapy of human beta-globin gene disorders. *Ann N Y Acad Sci* 850, 151-162.
- Phi-Van, L., Kries, J. v., Ostertag, W., and Strätling, W. (1990). The chicken lysozyme 5' matrix attachment region increases transcription from a heterologous promoter in
15 heterologous cells and dampens position effects on the expression of transfected genes. *Mol Cell Biol* 10, 2302-2307.
- Phi-Van, L., and Strätling, W. (1988). The matrix attachment regions of the chicken lysozyme gene co-map with the boundaries of the chromatin domain. *EMBO J* 7, 655-664.
20
- Piechaczek, C., Fetzner, C., Baiker, A., Bode, J., and Lipps, H. (1999). A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. *Nucleic Acids Res* 27, 426-428.
- 25 Poljak, L., Seum, C., Mattioni, T., and Laemmli, U. (1994). SARs stimulate but do not confer position independent gene expression. *Nucleic Acids Res* 22, 4386-4394.
- Schimke, R., Brown, P., and Kaufman, R. (1982). Gene amplification and drug resistance in mammalian cells. *Natl Cancer Inst Monogr* 60, 79-86.
30
- Stief, A., Winter, D., Strätling, W., and Sippel, A. (1989). A nuclear DNA attachment element mediates elevated and position-independent gene activity. *Nature* 341, 343-345.

Talbot, D., Descombes, P., and Schibler, U. (1994). The 5' flanking region of the rat LAP (C/EPB β) gene can direct high-level, position-independent, copy number-dependent expression in multiple tissues in transgenic mice. *Nucleic Acids Res* 22, 756-766.

- 5 Udvardy, A. (1999). Dividing the empire: boundary chromatin elements delimit the territory of enhancers. *EMBO J* 18, 1-8.

Urlaub, G., Käs, E., Carothers, A., and Chasin, L. (1983). Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. *Cell* 33, 405-412.

10

Walters, M., Fiering, S., Bouhassira, E., Scalzo, D., Goeke, S., Magis, W., Garrick, D., Whitelaw, E., and Martin, D. (1999). The chicken beta-globin 5'HS4 boundary element blocks enhancer-mediated suppression of silencing. *Mol Cell Biol* 19, 3714-3726.

- 15 Wang, Y., DeMayo, F., Tsai, S., and O'Malley, B. (1997). Ligand-inducible and liver-specific target gene expression in transgenic mice. *Nature Biotech* 15, 239-243.

- Wells, K., Foster, J., Moore, K., Pursel, V., and Wall, R. (1999). Codon optimization, genetic insulation, and an rtTA reporter improve performance of the tetracycline switch. *Transgenic Res* 8, 371-381.
- 20

Wurm, F., Pallavicini, M., and Arathoon, R. (1992). Integration and stability of CHO amplicons containing plasmid sequences. *Dev Biol Stand* 76, 69-82.

25

Other Embodiments

It is to be understood that, while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

30

WE CLAIM:

1. A method for transforming a eukaryotic cell to incorporate a desired gene or portion thereof, comprising co-transfecting into said cell:
 - 5 a first vector comprising a first promoter and a first gene encoding the desired gene or portion thereof, under the transcriptional control of the first promoter; and
 - a second vector comprising at least one chromatin element.
2. The method of claim 1, wherein said chromatin element comprises a MAR element.
3. The method of claim 1, wherein said chromatin element is obtainable from the
10 chromatin domain of the chicken lysozyme gene.
4. The method of claim 2, wherein said MAR element is a chicken lysozyme MAR element.
5. The method of claim 1, wherein said chromatin element is selected from the group consisting of SEQ ID NO: 1-5, or a fragment thereof.
- 15 6. The method of claim 1, wherein said chromatin element comprises SEQ ID NO: 1 or a fragment thereof.
7. The method of claim 1, wherein said second vector further comprises at least one additional chromatin element.
8. The method of claim 1, wherein said co-transfection is selected from the group
20 consisting of electroporation and chemical transfection.
9. The cell generated by the method of claim 1.
10. The method of claim 1, wherein said desired gene is selected from the group consisting of a structural gene and a regulatory gene.
11. The method of claim 1, wherein the desired gene encodes a polypeptide selected from
25 the group consisting of an antibody, an antibody fragment, an antibody light chain and an antibody heavy chain.
12. The method of claim 1, wherein said eukaryotic cell is transfected with said first vector and said second vector in a molar ratio of between about 1:2 to about 1:10.
13. The method of claim 1, wherein the method further comprises co-transfecting into
30 said eukaryotic cell one or more additional vectors.
14. The method of claim 1, wherein the method further comprises introducing into said eukaryotic cell a third vector, wherein the molar ratio of said first, second and third vectors is between about 1:1.75:5.5 to about 1:1.75:11.

15. A method for transforming a eukaryotic cell to incorporate a desired gene or portion thereof, comprising introducing into said cell:

a first vector comprising a first promoter and a first gene encoding the desired gene or portion thereof, under the transcriptional control of the first promoter;

5 a second vector comprising at least one chromatin element,
wherein said cell is contacted with butyrate.

16. The method of claim 15, wherein the concentration of said butyrate is about 10mM.

17. A method for transforming a eukaryotic cell to incorporate a desired gene or portion thereof by the technique of co-transfecting with unlinked vectors, the method
10 comprising co-transfecting the cell with:
a first vector comprising a first promoter and a first heterologous gene encoding the desired gene or portion thereof under the transcriptional control of the first promoter, and one first chromatin element; and,

a second unlinked vector comprising a second chromatin element.

18. The method of claim 17, wherein said first chromatin element is a MAR element.

19. The method of claim 18, wherein said MAR element is a chicken lysozyme MAR element.

20. The method of claim 17, wherein said first chromatin element is selected from the group consisting of SEQ ID NO: 1-5 or a fragment thereof.

21. The method of claim 17, wherein the second chromatin element is the same as the first chromatin element.

22. The method of claim 17, wherein said desired gene is selected from the group consisting of a structural gene and a regulatory gene.

23. The method of claim 17, wherein the desired gene encodes a polypeptide selected
25 from the group consisting of an antibody, antibody fragment, an antibody light chain and an antibody heavy chain.

24. The method of claim 17, wherein the desired gene encodes for a human anti-Rhesus D IgG antibody.

25. The method of claim 17, wherein the method further comprises introducing into said
30 eukaryotic cell a third vector, wherein said third vector optionally comprises a second promoter and a second heterologous gene.

26. The method of claim 17, wherein the cell is transfected with the first vector and second vector in a molar ratio of between about 1:2 to about 1:10.

27. The method of claim 17, wherein the method further comprises introducing into said eukaryotic cell a third vector, wherein said first, second and third vectors are introduced in a molar ratio of between about 1:1.75:5.5 to about 1:1.75:11.
28. The method of claim 17, wherein the first vector further comprises a regulatable gene expression element that permits regulation of expression of the desired gene product by administration of an exogenous molecule.
29. The method of claim 28, wherein the regulatable gene expression element is the Tet-regulatable element.
30. The method of claim 17, further comprising contacting said cell with butyrate.
31. The method of claim 30, wherein the concentration of said butyrate is about 10 mM.
32. The method of claim 17, wherein said first chromatin element is located 5' to said promoter and said first heterologous gene.
33. The method of claim 17, wherein said first chromatin element is located 3' to said promoter and said first heterologous gene.
34. A method of selecting a eukaryotic cell expressing a gene encoding a recombinant protein, comprising:
- a) transfecting a first eukaryotic cell with a first vector comprising a first promoter and a first gene encoding the desired gene or portion thereof, under the transcriptional control of said first promoter, and a second vector comprising at least one MAR element;
 - b) transfecting a second eukaryotic cell with said first vector comprising said first promoter and said first gene encoding the desired gene or portion thereof, under the transcriptional control of said first promoter;
 - c) measuring the expression of said first gene in said first eukaryotic cell and said second eukaryotic cell;
 - d) comparing the expression of said first gene in said first eukaryotic cell and said second eukaryotic cell; and
 - e) selecting said first eukaryotic cell if the expression of said first gene in said first eukaryotic cell is different from the expression of said first gene in said second eukaryotic cell.
35. A cell transfection composition, said composition comprising a vector comprising at least one MAR element having a sequence selected from the group consisting of SEQ ID NO: 1-5.
36. The cell transfection composition of claim 35, further comprising butyrate.

37. The cell transfection composition of claim 36, wherein the concentration of said butyrate is about 10mM.
38. A cell transfection composition, said composition comprising a first vector comprising a first promoter and a first gene encoding the desired gene or portion thereof, under the transcriptional control of the first promoter; and a second vector comprising at least one MAR element.
39. The cell transfection composition of claim 38, wherein said one or more MAR elements comprise SEQ ID NO: 1 or a portion thereof.
40. The cell transfection composition of claim 39, further comprising butyrate.
41. A eukaryotic cell containing a first vector comprising a first promoter and a first gene encoding the desired gene or portion thereof, under the transcriptional control of the first promoter, and a second vector comprising at least one MAR element.
42. A kit, comprising in one or more containers, two or more nucleic acid vectors, the first vector having a promoter and a heterologous gene coding for a desired protein, and the second vector comprising at least one MAR element, and directions for use thereof.
43. The kit of claim 32, further comprising butyrate.





Fig. 1

2/11



3/11




Fig. 3A

4/11




Fig. 3B

5/11




Fig. 3C

6/11



Fig. 4A

7/11




Fig. 4B

8/11




Fig. 5A




Fig. 5B

9/11




Fig. 6A




Fig. 6B

10/11




Fig. 7A

11/11




Fig. 7B

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074969 A3

(51) International Patent Classification⁷: **C12N 15/79**,
15/85, C07K 14/435, C12N 15/12

[CH/CH]; c/o Pactt, Rue de Bugnon 21, CH-1005 Lausanne (CH). **GIROD, Pierre-Alain** [CH/CH]; c/o Pactt, Rue de Bugnon 21, CH-1005 Lausanne (CH).

(21) International Application Number: **PCT/IB02/02137**

(22) International Filing Date: 28 January 2002 (28.01.2002)

(74) Agent: **BUGNION S.A.**; P.O. Box 375, CH-1211 Geneva 12 (CH).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/264,355 26 January 2001 (26.01.2001) US
60/281,391 4 April 2001 (04.04.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/281,391 (CIP)
Filed on 4 April 2001 (04.04.2001)
US 60/264,355 (CIP)
Filed on 26 January 2001 (26.01.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **UNIVERSITY OF LAUSANNE** [CH/CH]; Rue de Bugnon 21, CH-1005 Lausanne (CH).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MERMOD, Nicolas** [CH/CH]; c/o Unitectra, Schoenberggasse 2, CH-8001 Zurich (CH). **ZAHN-ZABAL, Monique** [CH/CH]; c/o Pactt, Rue de Bugnon 21, CH-1005 Lausanne (CH). **IMHOF, Markus** [CH/CH]; c/o Pactt, Rue de Bugnon 21, CH-1005 Lausanne (CH). **CHATELLARD, Philippe**

(88) Date of publication of the international search report:
24 December 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **MATRIX ATTACHMENT REGIONS AND METHODS FOR USE THEREOF**

(57) Abstract: The present invention relates to compositions and method for transfecting eukaryotic cells with nucleic acid vectors. In particular, the invention relates to uses of MAR elements to increase stable and transient transfection efficiency.

WO 02/074969 A3

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/IB 02/02137

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/79 C12N15/85 C07K14/435 C12N15/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, SEQUENCE SEARCH, WPI Data, PAJ, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>ZAHN-ZABAL M ET AL: "Development of stable cell lines for production or regulated expression using matrix attachment regions"</p> <p>JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 87, no. 1, 27 April 2001 (2001-04-27), pages 29-42, XP004231294</p> <p>ISSN: 0168-1656</p> <p>the whole document</p> <p style="text-align: center;">--- -/--</p>	1-43

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- * & * document member of the same patent family

Date of the actual completion of the international search

29 April 2003

Date of mailing of the international search report

13/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

De Kok, A

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/IB 02/02137

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GREENBERG N M ET AL: "The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice." MOLECULAR ENDOCRINOLOGY, vol. 8, no. 2, 1994, pages 230-239, XP000197058 ISSN: 0888-8809	1-4, 9, 10, 38, 41
A	page 233, column 2 -page 234, column 2	15-19, 22, 34, 42
X	--- DATABASE EM_OV 'Online! EMBL; 16 July 1990 (1990-07-16) STRAETLING, W.H. ET AL.: "Chicken lysozyme gene intrinsically curved segment of DNA" retrieved from EBI, accession no. CLCURVAS Database accession no. X52989 XP002239322 abstract	35
X	--- DATABASE EM_OV 'Online! EMBL; 11 February 1995 (1995-02-11) STRAETLING, W.H. ET AL.: "Chicken lysozyme gene promoter" retrieved from EBI, accession no. GGDNALGP Database accession no. X84223 XP002239323 abstract	35
X	--- DATABASE EM_OV 'Online! EMBL; 14 July 1996 (1996-07-14) STRAETLING, W.H.: "G.gallus lysozyme gene 5' matrix attachment region (MAR) subfragment B-1-H1" retrieved from EBI, accession no. GGB1H1 Database accession no. X98408 XP002239324 abstract	35
X	--- DATABASE EM_SY 'Online! EMBL; 17 May 2000 (2000-05-17) MAGGI, A. ET AL.: "Cloning vector pMAR, luciferase reporter vector containing MAR insulator sequence" retrieved from EBI, accession no. CVE277960 Database accession no. AJ277960 XP002239325 abstract	34
A	--- WO 97 46687 A (NOVARTIS AG) 11 December 1997 (1997-12-11) page 2, paragraph 3 -page 3, paragraph 1 --- -/--	1

INTERNATIONAL SEARCH REPORT

In pat Application No
PCT/IB 02/02137

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GORMAN C M ET AL: "EXPRESSION OF RECOMBINANT PLASMIDS IN MAMMALIAN CELLS IS ENHANCED BY SODIUM BUTYRATE" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 21, 1983, pages 7631-7648, XP002054816 ISSN: 0305-1048 the whole document	15,16, 30,31, 36,37, 40,43
A	CHEN CHAO ET AL: "Cointegration of DNA molecules introduced into mammalian cells by electroporation." SOMATIC CELL AND MOLECULAR GENETICS, vol. 24, no. 4, July 1998 (1998-07), pages 249-256, XP001091245 ISSN: 0740-7750 abstract	1,8,9
A	WO 00 32800 A (DOW AGROSCIENCES LLC) 8 June 2000 (2000-06-08) the whole document	1,2,15, 17,18, 21,32,33

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/02137

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1, 9, 15, 17, and claims depending thereon, all partially
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1, 9, 15, 17, and claims depending thereon, all partially

Present claims 1,9,15,17 and claims depending thereon relate to a method defined by reference to a vector having a desirable characteristic or property, namely comprising at least one chromatin element.

The claims cover all vectors having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only ONE of such a vector, i.e. vectors comprising matrix attachment regions (MAR). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT), as the chromatin element is not defined in structural terms. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the vectors wherein the chromatin element comprises a MAR, i.e. the subject-matter of claim 2.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Int 1st Application No

PCT/IB 02/02137

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9746687 A	11-12-1997	AU 718551 B2	13-04-2000
		AU 3256297 A	05-01-1998
		CA 2256484 A1	11-12-1997
		WO 9746687 A1	11-12-1997
		EP 0914444 A1	12-05-1999
		JP 2000514284 T	31-10-2000
		NZ 333188 A	29-06-2001
		US 6194212 B1	27-02-2001
WO 0032800 A	08-06-2000	US 2002103148 A1	01-08-2002
		AU 1833100 A	19-06-2000
		EP 1135512 A1	26-09-2001
		JP 2002531097 T	24-09-2002
		WO 0032800 A1	08-06-2000

10210 1700 00 0000 0000

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)